// App-Quantinova.ai

AB1185 : BUDGET IMPACT ANALYSIS OF INTRODUCING SUBCUTANEOUS INFLIXIMAB CT-P13 SC FROM THE UK PAYER PERSPECTIVE

Researchers

Presenter

  • M. Perry

Principal Investigators

  • M. Jang

Medical Centers

  • Royal Alexandra Hospital, Glasgow, United Kingdom

  • Celltrion Healthcare Co., Ltd, Incheon, Korea, Rep. of (South Korea)

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • BCL2 like 11

Drug/Treatment

  • Infliximab

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Grifols

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved